Data from Pharmawand - Curated by Marshall Pearce - Date added 20 March 2017
New data supports the use of Abbott's CardioMEMS HF System as an effective real-world approach to reduce heart failure hospitalizations and combat the rising cost of heart failure. Researchers found a 46 percent reduction in heart failure hospitalizations in patients six months after receiving the CardioMEMS HF System, and a 34 percent reduction at 12 months post-implant. The data are consistent with what was seen in the CHAMPION clinical trial, further confirming that when physicians adjust medications based on the patient's pulmonary artery pressures, related hospitalizations are significantly reduced. The data also showcased important cost-savings captured through reductions in heart failure hospitalizations associated with the use of the CardioMEMS HF System. In particular, in the six months post-implant, each patient had an average reduction of more than $10,500 in comprehensive health care costs compared to the six months prior to implant. Twelve month post-implant analysis showed a $13,190 reduction in costs per patient.
The CardioMEMS HF System is the only U.S. Food and Drug Administration-approved monitor that, when used by physicians to manage heart failure, has been shown to reduce heart failure hospital admissions and improve the quality of life in patients with heart failure (NYHA Class III). The research was presented during the American College of Cardiology (ACC) 66th Annual Scientific Sessions.